| PROTOCOL CODE and DESCRIPTION |
AVAILABLE DOCUMENTS
(revision date indicated in red) |
| BMTLPDRIT: Pre-Emptive Rituximab Therapy of Epstein-Barr Virus (EBV) Related Post-Transplant Lymphoproliferative Disease. |
- Protocol (01 Feb 2011) |
| BMTMM0301: Conditioning therapy for autologous stem cell transplant using high dose melphalan in the treatment of multiple myeloma. |
- Protocol (01 Jul 2010) |
| BMTIVBUCY: Myeloablative conditioning therapy prior to autologous and allogeneic hematopoietic stem cell transplantation for myeloid malignancies using IV busulfan and cyclophosphamide. |
- Protocol (01 May 2009) |
| CMLIFNCYT: Therapy of chronic myeloid leukemia using interferon and cytarabine. (Deleted 01 Jan 2012) |
- Protocol (01 May 2009) |
| LKAMLCYT: Therapy of Acute Myeloid Leukemia Using Low dose Cytarabine. |
- Protocol (01 Jan 2012)
- Preprinted Order (01 Jan 2012) |
| LKANAG: Anagrelide as second-line treatment of thrombocytosis related to myeloproliferative disorders. |
- Protocol (01 May 2009) |
| LKCMLI: Therapy for chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia using imatinib. |
- Protocol (01 Feb 2011)
- Preprinted Order (01 Feb 2011)
- Patient Handout (01 Feb 2010) |
| ULKCMLD: Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Dasatinib (SPRYCEL®) |
- Protocol (01 Feb 2011)
- Preprinted Order (01 Feb 2011)
- Patient Handout (01 Feb 2010) |
| ULKCMLN: Treatment of Chronic Myeloid Leukemia Using Nilotinib |
- Protocol (01 Feb 2011)
- Preprinted Order (01 Feb 2011)
- Patient Handout (01 Feb 2010) |
| ULKMDSA: Therapy of IPSS Intermediate-2 or High-Risk Myelodysplastic Syndrome with Azacitidine |
- Protocol (01 Mar 2011)
- Preprinted Order (01 Feb 2011) |
| ULKMDSL: Therapy of Myelodysplastic Syndrome using Lenalidomide. |
- Protocol (01 Oct 2010)
- Preprinted Order (01 Oct 2010) |
| LYCODOXMR: Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Leucovorin (CODOX-M) and Rituximab |
see Lymphoma page |
| LYIVACR: Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab |
see Lymphoma page |
| MYHDC: Single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant. |
- Protocol (01 Dec 2009) |